NRG-GU013: High Five Trial - NRG Oncology
NRG-GU013 is a clinical study for people with high-risk prostate cancer. Currently, patients with this type of cancer are treated with surgery, radiation, or hormone therapy drugs that are …
The “High Five Trial” for High-Risk Prostate Cancer Activates ... - NRG
2023年12月11日 · The NRG-GU013, also known as the “High Five Trial” activated to high-risk prostate cancer patient enrollment in November 2023. Trial participants will be stratified by …
NCT05946213 – NRG-GU013, “The Phase III ‘High Five Trial’ Five …
2024年7月24日 · This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to …
NRG-GU013: THE PHASE III ‘HIGH FIVE TRIAL’ FIVE FRACTION …
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over …
NRG > Home
NRG Oncology and its partners have more than 150 years experience in conducting practice-defining, multi-institutional phase II and III trials sponsored primarily by the National Cancer …
PhIII HighFiveTrial Five Fraction Rad for HighRisk Prostate Ca
2024年2月15日 · This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to …
The Phase III ‘high five trial’ five fraction radiation for high-risk ...
To compare metastasis-free survival, determined using conventional imaging, between men with high-risk prostate cancer randomized to ultrahypofractionation (SBRT) to those randomized to …
Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 …
2023年7月1日 · Purpose: The combination of cisplatin and radiation or cetuximab and radiation improves overall survival of patients with locoregionally advanced head and neck carcinoma. …
Prostate Cancer Risk Stratification in NRG Oncology Phase III ...
2024年10月24日 · Purpose: Current clinical risk stratification methods for localized prostate cancer are suboptimal, leading to over- and undertreatment. Recently, machine learning …
Pembrolizumab plus chemotherapy in advanced or recurrent …
2025年3月5日 · In the phase 3 NRG GY018 study, pembrolizumab plus chemotherapy significantly improved investigator-assessed progression-free survival (PFS; primary endpoint) …